N
Google TrendGME (1000+) — GameStop Stock Hits a New 52-Week High: What's Going On?
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:gme1000+pope francis200+nicolò tresoldi500+michael olise1000+bank of america fine1000+club brugge500+rb leipzig200+saudi news1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Small Biotech Survival: N" (30 stories)

Top Headline Story

Small Biotech Survival: Navigating Risk And Capital Scarcity With AI
Lead StoryClinical Leadertech
May 8

Small Biotech Survival: Navigating Risk And Capital Scarcity With AI

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQdXNVVmZ1UTZPU1daekdHeUtxRHFfNFozYWtJWUdFT2VUMGhabWVuVTI4cDByUzZZbFp3U09mZ1NvNjYxUjA2SjFZbGI0SE91bWxVZmhaZDMtNW51R0dKUWV0LWx6aXh2b1YzLUt0WTkxU0hxNmJrcnFseERsd3NnVEpodmhNaWR5TWpWTFY2RDJTRWFMOU5EcHhxaDVZS2dWcWF1YjlKNE9QekE?oc=5" target="_blank">Small Biotech Survival: Navigating Risk And Capital Scarcity With AI</a>  <font color="#6f6f6f">Clinical Leader</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
1000+24m ago

gme

GameStop Stock Hits a New 52-Week High: What's Going On?

Filter stories
200+24m ago

pope francis

The Myth of St. Francis

Filter stories
500+34m ago

nicolò tresoldi

Nicolò Tresoldi, chi è l'attaccante del Bruges che spaventa l'Inter in Champions League

Filter stories
1000+34m ago

michael olise

The Ballon d’Or doesn’t capture football’s wonder – Michael Olise is proof | Zito Madu

Filter stories

Search Results for "Small Biotech Survival: N"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
TradingViewtech

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPT1VVMDMwSjdTSnVIb3BBdEtUcWl0T3psU0xLN3ZIVm95M2Joalp6VkY5ZzVwQnFXd1ZZWmdfWXNXN05RM1lBT0RJZHdKN3Q0WXJsOXdWY21IbUR2NVo5YmptRFh2a01mRG9COG5qNFV5WmZ4dGhaeDF6SDd2TG5BRGNEYy1uclRfRjdDSnlQYXJFR3h6NFZsa0hUckVDMzdRdTAyUWRBYlh5ZHUyUnlnNXBNVlZsQQ?oc=5" target="_blank">Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate</a>  <font color="#6f6f6f">TradingView</font>

Read Full StoryMore like this
About 30,000 new lung cancer cases occur yearly in Spain and Portugal; a trial has approval to screen patients there.
Stock Titantech

About 30,000 new lung cancer cases occur yearly in Spain and Portugal; a trial has approval to screen patients there.

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQM2gwUlZ3c0d0cUVjM2VlS0tYTVRuVmNMSDdNNWNIM0ZtXzRRVHN6TFlJR1pBbmxCVms5YjdTNVg3X0R4bUpFUWUwaVVvbmRlR2ZSdEFQQ0VlcjZ2Mk5hbkkxOEJrc3RoRlNWZnpHcWppRlE2dUV2Mi1DU01hcV9LeDNkQThXOTFIbldYNUctalh6SUVpem1saDFQN25hMnJmQ2VBektBRWViaktyMmw0SlZCc2NDaXpFZXM3bXBR?oc=5" target="_blank">About 30,000 new lung cancer cases occur yearly in Spain and Portugal; a trial has approval to screen patients there.</a>  <font color="#6f6f6f">Stock Titan</font>

Read Full StoryMore like this
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
Fierce Biotechtech

BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPOThxMnV4N0N3Y1hLMmEzbWZaanNlSzdpQVFyckt3WFlhRU1rd0wyeURKS1FmcXk1dllmb1VPUnA0UjB4YmgtR1hQOWttVl9mRHZneTFHeGdGVlM2aExidWxIaktMNzNxQ3dMUjBHUWlRNWpkZlJ4aVZpX3ZjY1VvTEt5LUVVVXk5MDVIc25DNWZiMGxiYUpkS202NlRpci1teG5jdExBMDRRTldfLUE?oc=5" target="_blank">BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
STATworld

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPa0IwNjlEME5qcng3dktzVTlKdC00WG9tM0VpVHU5dmVRaVVjbUFEamhjOHlsR1AzXzBnS1hYR05TbnZQRnJrRnJ0blVWS0NxejdoZWpCV2RKSGN5UzJyVk1sZ0tEdm5FbDFmR1JUdmZuamp3b0hyLWgzc0xERExDVmNjSzFOSzd0MEZVUS11UmRWN0EweEFDVw?oc=5" target="_blank">Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer</a>  <font color="#6f6f6f">STAT</font>

Read Full StoryMore like this
Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival
BioSpacetech

Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOZnMxNWNYOEc5WUxoUG5hVVYxZTk4LUloMGRraG9idjU2Qi1YdFRsV0U2NHZPQ2N6VWlqZnVRcWdkY2JqS090R0VCd0puUllfUnJMWUFJRDdYT0NhOHFxd3FycVZSdWhrbDVZTnNQSG51bXE5R0ZHcm8teHpPLXpiNmw5ZW9kTlRaaUs2bGN5ZXhaWERWcDRIUDlYZ2ZsU3pJWVpGRllaVi1RVEpyQ3oyQTVsbXFOSnBhc3JmOVNGVXI?oc=5" target="_blank">Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Kelun, Merck's lung cancer combo improves survival in late-stage China trial
Reutersworld

Kelun, Merck's lung cancer combo improves survival in late-stage China trial

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxPUzFCcVVwMFFHZ0FvQlFCXzNxWFcwMXdPcm9LRklMdXROVmpWTjd6b3B1emZWRy03cEJwWW40YThzM3RFVkVDbWJfeXN3N1RXQzB3NWVNTW13V1ZWQkN0XzFPckJSY2Y2OWYzNEYwUUtYYVVSSnVxc1RYYTktQ1gzQ25nVGVORU8wT24ydl85ekNwXy1ybzdfRHdwMjFraGJ2enRpeVA4MFNHbDF2bUVYbmFoTUYyWFdETmkyNmJ5N3hGbms0a0IzRkg5NF95ZkZUWTVnR3hwVjJZUHM?oc=5" target="_blank">Kelun, Merck's lung cancer combo improves survival in late-stage China trial</a>  <font color="#6f6f6f">Reuters</font>

Read Full StoryMore like this
Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer
Fierce Biotechtech

Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQQjEwNnZfZTlaRXRrTFoyNTdKMXV2ajZxR2UwZnVYUHI5M3dnU3F1NGFxa0k2YkQtSldJVmhDX2h6R1FqU2VvR1Z0ZlhQdUtiQVYzVEpQbkhoVnQ0NW5COUtpTENWRlBsa1BGQko3dVliWTk4U3ZhMVB0ZDlEZkFPV0xqUk96bUVJekdrSlNOeTBGQWxjWFFZTWV1cXdscjA0UUpTSURLN1BDb1QxUXFna01xaW1MdTVzVGc?oc=5" target="_blank">Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer
Fierce Pharmaworld

ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQUzFBTXBoS0czcDZ3NTJzRkdRQWV4LXFUSTRHYjQwemR5WWZYejVudFVXR3VDR1ZOTjVCNUxQUlJQNG9jamk0dWZDQXUtMTlSSE1sSWNqSDRzSURvV0lVaUpnVmwwdm5qVkNrX0FiSGwyRGZINUdjNWxBUVV3Y2pmU1NSTGhTWUctd3VIMEdYU2ZGLTItZUZDU1ltSUF2TEloc0JmN1FlWGl4Tm9zdlBPWFZ6OE80dldTaXc?oc=5" target="_blank">ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer</a>  <font color="#6f6f6f">Fierce Pharma</font>

Read Full StoryMore like this
Immutep cancer candidate shows strong median survival in lung cancer as company considers conflicting trial results
BiotechDispatchworld

Immutep cancer candidate shows strong median survival in lung cancer as company considers conflicting trial results

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxOUTBRb09aUUZ6YnUwbnJMOTlUV3kwNklDNnIyTVAzVTdDRjE2Z0ZCQUs2eHo2RzZYSXVxdWNWbFZsU09Ud2tBMDRTN21uTk9HcFNzQ1l1alhzUmNoWkJ6TDhkV3VmSDIwSExfM3dWekZRdWpuNG5KMHU1b0hjVkg3UlhaSGZsWkc4NWhHMGQ4bS1aVXVhZGtSd0x6NFh1dUF1S3R0WnhWVHllWmt6bDl1S0Zuc1RLWFkwd2czZGFBSUJtTjNINkViTE0td1I?oc=5" target="_blank">Immutep cancer candidate shows strong median survival in lung cancer as company considers conflicting trial results</a>  <font color="#6f6f6f">BiotechDispatch</font>

Read Full StoryMore like this
AstraZeneca (LSE:AZN) Posts Phase III Survival Win In Small Cell Lung Cancer
Simply Wall Streetworld

AstraZeneca (LSE:AZN) Posts Phase III Survival Win In Small Cell Lung Cancer

<a href="https://news.google.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?oc=5" target="_blank">AstraZeneca (LSE:AZN) Posts Phase III Survival Win In Small Cell Lung Cancer</a>  <font color="#6f6f6f">Simply Wall Street</font>

Read Full StoryMore like this
GSK sees phase 3 win for Hansoh-partnered ADC in China as validating its ‘priority asset’
Fierce Biotechworld

GSK sees phase 3 win for Hansoh-partnered ADC in China as validating its ‘priority asset’

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxONGJOTlhyVGx5LVprZkJpcW5mNnJXUzZxWUpZcEpLZ3NFaFRIMjBJSE9EU2NiaUEwV0VlY0pRNFNlcUVVSkk4emN6ak51VUFITFFMOTZPeTVhVVg2WFViY2hJU0E1U0tuZ3dyMVYtTHZ2UFdYcFBjc3JEWEFvZkl6Z2dIYUdmVlE5REhveWV0Q2lPOXhoaU5MZUNWZzdPRWNsR0tR?oc=5" target="_blank">GSK sees phase 3 win for Hansoh-partnered ADC in China as validating its ‘priority asset’</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck
Fierce Biotechworld

GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxObHJWSUQwVEl1V1JOQjZJQkJGRmY2c1BaVWlHc19sZExobUJNd2tsQ2xjeGtoeGFzS2U4WTNSUGVhdS0wa3VIdUNzTF94NVg4RnU5Z1NjejZVLVl3RVFuTXByanJKVDdOOHRoQ1pVRVpqcHhndmVBU3BjeEtMYk9MVThGZDlNVWpnOG9lTVg5aDlhb0Vz?oc=5" target="_blank">GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
Preserving US Biopharma Leadership: Why Small, Research-Intensive Firms Matter in the US Innovation Ecosystem
Information Technology and Innovation Foundationgeneral

Preserving US Biopharma Leadership: Why Small, Research-Intensive Firms Matter in the US Innovation Ecosystem

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQYVM5eXpkd3oxaGU1T2JQaEU0NnV4RjdOQzk4MDZaX1JUUzVPWDlaRTA3YlZVQ3Rua0Rzd2lEektJQ3pSVFpHa2dWTjk4ME5teWR5Vlo5SHJkaUdCWmdVaW91UUE2RENWSVhDdHluZkQwVE0xV1ZPTGFDSHRqcm1OcjhHM2tMUlJoeWlDVEpid0dOUGZ1UFJSVlNxLS1JaEFNZ1ZmSUtUZTl6VUFwUWlPRnFVejcxSjNRT0E?oc=5" target="_blank">Preserving US Biopharma Leadership: Why Small, Research-Intensive Firms Matter in the US Innovation Ecosystem</a>  <font color="#6f6f6f">Information Technology and Innovation Foundation</font>

Read Full StoryMore like this
Building Biotech's Future: The Strategic Imperative Of AI Integration
Life Science Leadertech

Building Biotech's Future: The Strategic Imperative Of AI Integration

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxNc2lsLTRpaU82UTJZNVNnY3M4aHVvZ0ZnTE5Hc28xdUlPUkYxbzlpWXVmb2RaeFlkVjFacEpoVTcyNjUtak1RZ2w4OGtmUTVCNGZfTmxJRjdOSG5JVnZyOHpobGVocVFxbS16T3ByV1VwVjJaWEVZUzRNUlBMWk50MUtoTTJ1TnR0UHVfdjh6UlRRLWhZWTZUcFQtRzJwQlZacTFZVE5CLUJDMTlwcHFJQg?oc=5" target="_blank">Building Biotech's Future: The Strategic Imperative Of AI Integration</a>  <font color="#6f6f6f">Life Science Leader</font>

Read Full StoryMore like this
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
Fierce Biotechworld

AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxOc0lEbGlDQ3JtSEVqMjMxN0ZyWG4xN0NIQ1k1bEItb0NKZ2wybmZrazdjQXVtT1FkVnV3TjdpakVxYWo4SWQ1VkpfMDZKd2ZjeVlxSkdkMWk3VDM3d1A5alpDVmJCZmMxWVZ2d1RpWkd2aFlabWQ2RENFaG1feVVCZF9oazZzTFRaZkN6R1Axd2JmaVBhdk9jRGRuTUI0cGdnUEFJbHBxQWEweDNjV2NsQ2ZVMnY5c2dHTDdLajRyQjlQNGs?oc=5" target="_blank">AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
Akeso says its closely watched drug improved patient survival in a lung cancer trial
STATworld

Akeso says its closely watched drug improved patient survival in a lung cancer trial

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxONU9QUVhick9iRU5YZWZDN0NFdGYzdW5iMkRCcENpcEJIR1BXWG92c0pMd044MGpqZWExZ1duMHBKbkl5TkVGOVlubGh3NE83WjZPT19CMjB6cUs4UWR6ODhCcE5KRnJGTXdDbkl3cjhWUjlabHlRb2RCZU8xajJnU25NWWpaX18za1B1eE9ISjJ5U0RMc296WWtCNzZ2c1NCS3ZGYllPSHZqblVSSzRkc25FUW1DRXc3M3VNZjZn?oc=5" target="_blank">Akeso says its closely watched drug improved patient survival in a lung cancer trial</a>  <font color="#6f6f6f">STAT</font>

Read Full StoryMore like this
Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial
Fierce Biotechgeneral

Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOUzZFaGp1dnFqUkxtM1NZTmkxQmd3ZHNwOExkd1hrd0Y0eWpKeWtUb05xRFp4QnNEWXN3TGpCWFdsVzhYS2xFaVl0aWFNb2pGbGlZZlZuT1YtN0JRUUhQZDRmaGNBYTRockwtbUhLdllycGkxSzVuc2JnQ1VtWHl0MmtjX0NyZmlxb0tWWFlVczlGeVppUlJvRUE0QkQyWFpyMnB5Z0ZuWWk3aUIxcWRfRHA5VFd5ZGVvTjBhTFBocUVxZw?oc=5" target="_blank">Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial but poses tolerability challenge
Fierce Biotechtech

BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial but poses tolerability challenge

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOSHFyS3EwQ3ZaNnlscnJjanl1SFlSdTZiWlVIam1udW5jUE5ZMkFPelJ5UTh0YkNyNDFyYVUwdHdoVEU0N1drQndaM2VhUUU1cjVnNDlHTGJFUllkZFIyVWZuamJpVnh0YlVWcHNwWEZkNS1oMWdtQWVJTnBlcW1pX3B4amU3M2hQV2ZET1I0WUxjeU5nZUJlWVZLcXhKRjBSMjRuVV9VQ3VSWlhxSUZMNm95MXdZbHQ4TndrSng4WS16eGlDLVE?oc=5" target="_blank">BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial but poses tolerability challenge</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
The 10 highest value R&D projects in biopharma
Fierce Biotechgeneral

The 10 highest value R&D projects in biopharma

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPa0s0R1ZNUTlScEZyaVpLNDBVQTh5QjQtMzhmS0RTamJ3djZuak50UWJLcmU5S1RzZHZicjFDRlpjTkdoTjd5Nzl2NGE5eWE5RDlFNmVOUlF0QVpKMkhwRWtUX05lZG5UOXZmRmZfMGFfS0ZRSWY0dW9pVEZzVmxIV0FPcU41NHhuN05LRg?oc=5" target="_blank">The 10 highest value R&D projects in biopharma</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy
ImmunityBioworld

ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

<a href="https://news.google.com/rss/articles/CBMijAJBVV95cUxOcnZCTUZ6RS1Ud0JkZWhfUklpNVlwNWlYRDlwcm44YlE0LUJEZmhjel9hY3JtOEd4Q3ViNGVSVVpuQWpTdHk4bDBUaWZNblV4NWlBeWo4a1R2QzBBVjFOZnNzVTVoSlJBWmVqUFBaZWhpek1iMC1Zc1NVdl9rWFBILUdiR282REgxMVBZeWRSa1E3Q1V2RWxCVERRelplb0tRWGtfOHhfbGdaOE11a1ZMclZ2Y1duSlo2bTJsTmtCbkV3R29UNzFCeE9pNDlEWUx2cXZvMEY3OUl1SEdPc2lTS3RFNGkwbkN5ekxTdU9iZG1NaFpObUhQeDJieG51QzdsOGtITmUzUEIxcE96?oc=5" target="_blank">ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy</a>  <font color="#6f6f6f">ImmunityBio</font>

Read Full StoryMore like this
‘Holding on by its fingernails.’ The biotech industry in Massachusetts braces for another tough year.
The Boston Globetech

‘Holding on by its fingernails.’ The biotech industry in Massachusetts braces for another tough year.

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQT2cxUlFxNjhYNzFRSUdNYlg2Qjgtd2xWUm1Rc2Rjam1ONmpfNUlPNGJNYmRtYlQ1bWZlM3dxbHgwQUd0djZmR2V3aUdMSWdCMmFfa2RnWFdXTDBEbHQ2cWhtVlFkdGotczNWQ29MTVJWSGNJVkhwa3Q5bUR2dFdxSW9TWXNmbEpZNWQ2OWU1Y2FqNGdkZ0pGNUNvNnpiUURnYVpWa3N2ZEhQVHZHVTFBUHBqelBPVWQxakE?oc=5" target="_blank">‘Holding on by its fingernails.’ The biotech industry in Massachusetts braces for another tough year.</a>  <font color="#6f6f6f">The Boston Globe</font>

Read Full StoryMore like this
Investing in oncology: a biotech revolution in research, diagnosis, and treatment of cancer
Tema ETFstech

Investing in oncology: a biotech revolution in research, diagnosis, and treatment of cancer

<a href="https://news.google.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?oc=5" target="_blank">Investing in oncology: a biotech revolution in research, diagnosis, and treatment of cancer</a>  <font color="#6f6f6f">Tema ETFs</font>

Read Full StoryMore like this
ASCO: Early Purple data gain ground in metastatic pancreatic cancer
Fierce Biotechtech

ASCO: Early Purple data gain ground in metastatic pancreatic cancer

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOWXdpeGRzNThnR0tvVGRWV2dPeFJxbVdiSE13dEtWZVNqRGtBRC0yN1hick5td3NseTh5RFhZdVJ5MHJWOUpfNTF2Y1pKRFQtQ29jUTNOeDQ4Mjh0VG1xZ1M1eHZ3cDJ4enJkRkx2ZHBRMVZNclhMcTBLRGtLMm5DVEsyTE1KRWtSbjZSemRFUXF0RUYySWVBa2Jkd3BDNjg1ekc0UEJQRndIenBQZlp3?oc=5" target="_blank">ASCO: Early Purple data gain ground in metastatic pancreatic cancer</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
PDS0101 Plus Keytruda Elicits Survival Response in Head and Neck Cancer
Cure Todaygeneral

PDS0101 Plus Keytruda Elicits Survival Response in Head and Neck Cancer

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNd2ZkX2JFV2xmTDRmQ2tGRnBlVkM0dGt2SVExWkpTcE9BbE1Fam9Yb3V3MnlBZGt1dzR5SkRxdWVhMjhoSGNxZ3RDT3MxbmxjSHdxNjF0dl9ZbGtoMlpPUXlfSzIzcUpHVHFaeXlqa1NiRW9fbDlnUWJrU1BVRHBWUFFtVjBXcm5hd2MzaFoxTk9YcERkY2VsNTl1OTlONVY1LV8xSg?oc=5" target="_blank">PDS0101 Plus Keytruda Elicits Survival Response in Head and Neck Cancer</a>  <font color="#6f6f6f">Cure Today</font>

Read Full StoryMore like this
IceCure's cryoablation treatment may extend survival in some lung cancer patients, study finds
Fierce Biotechworld

IceCure's cryoablation treatment may extend survival in some lung cancer patients, study finds

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPc2xsSWw5aUVCdUctN1hHTDBIVzJBeUl5WUlRVWRjdUlSUTR4ZmFKcE5za1NXa0d1UVNtUU4tRFF6empkS3dKZlU4VGtkcmlMV0RqVnE0Rm9IZDFUVmFzLWhRNllHS3E4NmxIVWlSVHZqX1hlamdad0JKX01GT1p3SlY1Qjd0WEl5TTUwbmZiWlV3YURud2t4WEFOb0FCYW9Fa3dJWDMwb1lhY18weEJ0QzlKSDhHTFE4SEsxVjJVcmxsT1NOaUE?oc=5" target="_blank">IceCure's cryoablation treatment may extend survival in some lung cancer patients, study finds</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
PR Newswiretech

Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint

<a href="https://news.google.com/rss/articles/CBMiwAJBVV95cUxPYkg3WDJWOGoyMUdybXhzV200eXM3eWVGcXYzT2VMVWViVVhmYlZiMFZJUXd2aFF1Tnd4R2Ntd3B5YXFCSmpXdEdlM1BjejhIYktzMGdRcExBajl6MF9XU1hxb0lkbTg5VmZ4Y1V4YmZ0MVUtOFQ4dDRHcHBkNlljOFgzR0hkNExMWTRXRmpNNXlfZUlCS3FndVhpdGhGSnQtRWZHQkR0MzJ2b3hWN2ROYmdyM0g4M3dUTGs5VU9wVXNOR1gxNlFDdGs3T0JsSlRKWmM3T0F2T1BoUXBoNFdYTHVGWnRIX1V1UkZIQVBHZVJTcThqUGUyR0gwdVZfZ0tnNmdnWjlMaWt6TS0weUcxd1VPbWJ5UUxTQmxhbVQzTVJRdUFmOU9rbTdtY2NQQ0hjY1RYT0NPaG1NckJGNkVtMQ?oc=5" target="_blank">Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Clearance of intracranial debris by ultrasound reduces inflammation and improves outcomes in hemorrhagic stroke models
Natureworld

Clearance of intracranial debris by ultrasound reduces inflammation and improves outcomes in hemorrhagic stroke models

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9wMG8xNmQtTGpzWk93MzctZEdTb2htY0c5eUtUOS1INk92TzRveUVrQVpTc0pBMkhaSHNxaGZ0LS0xMmlKTEp2dVhiZnlGcEViNUsxOGZwZWRUS0VjLUtJ?oc=5" target="_blank">Clearance of intracranial debris by ultrasound reduces inflammation and improves outcomes in hemorrhagic stroke models</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda
BioSpaceworld

Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQYXZNcW5tdFFSUE85bEkwMDdtQi13TGFHT3h5OFdKeGhWTnE1WkVwRnp3ajJqc212eWZJYnZ3Zm5qUXJ1eWc2Ul9qSTI4NHRFS2JEajAzc2hsU19xc1prendKUEZ6NjZDSlE2WjBDOGg0bEdaVDNKOVRFRnkxTTh4eTlvbU42SWllRFE4SGdVYmlHSzEtVU5XMm9NcDl3RFJycWZiVDZHM3NOX1VQNm1kUWlHTDdDSTQ?oc=5" target="_blank">Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Watch these 9 small molecule drug discovery companies in 2025
Labiotech.eugeneral

Watch these 9 small molecule drug discovery companies in 2025

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxQOTVpUWlhVTN2X0tCY2U1N1NiZWw0SXc4ZHE0bHNKZk9IeXYzcTJ2Mnl0aEV0ZkZUQkl3T0dOSmxsNXcyRHR0MzJFazZSeGZLRDFsRWJ5X0s4MmJsQ3FTbWpVeUJidndPa3Q2S1Bmc0taZVJHNkVDSS1yaUdsbEEwbEtENU0?oc=5" target="_blank">Watch these 9 small molecule drug discovery companies in 2025</a>  <font color="#6f6f6f">Labiotech.eu</font>

Read Full StoryMore like this
"Small Biotech Survival: N" — Live Google News Trends & Headlines